Clinical utility of MRI biomarkers for identifying NASH patients ’ high risk of progression: A multi-center pooled data and meta-analysis

Non-alcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide. NAFLD is associated with excess risk of all-cause mortality, and its progression to non-alcoholic steatohepatitis (NASH) and fibrosis accounts for a growing proportion of cirrhosis and hepatocellular cancer and thus is a leading cause of liver transplant worldwide. Non-invasive precise methods to identify patients with NASH and NASH with significant disease activity and fibrosis when the disease is still modifiable are crucial.

Source: Clinical Gastroenterology and Hepatology - October 6, 2021 Category: Gastroenterology Authors: Anneli Andersson, Matt Kelly, Kento Imajo, Atsushi Nakajima, Jonathan A. Fallowfield, Gideon Hirschfield, Michael Pavlides, Arun J. Sanyal, Mazen Noureddin, Rajarshi Banerjee, Andrea Dennis, Stephen Harrison Source Type: research